Frontiers in Pharmacology · 2020 · 107 citations · 27 references
Life SciencesNeurosciencePharmaceuticsDrug DeliveryMolecular NeuroscienceNeurodegenerationAlzheimer DiseaseBrain Targeted DeliveryNanomedicineNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionAlzheimer Disease NeuroprotectionBrain Targeting LigandsCerebral Ischemia NeuroprotectionIntranasal FormulationsNanoparticlesNeural Cell DeathProtective TreatmentsSmall Molecule Brain Targeting
Effective treatments for neurodegenerative diseases need to be developed. MiR132 is abundantly expressed in the brain, and it modulates neuron morphology and plays a key role in maintaining neuron survival. Regulating miR132 can effectively improve the symptoms of Alzheimer's disease. It can also reduce cell death after cerebral hemorrhage, improve the microenvironment of hematoma lesions and provide a certain protective effect from brain damage after cerebral ischemia. MiR132 has great potential in the treatment of cerebral ischemia and Alzheimer's disease. To prevent the decline of miR132 of miR132 levels in the blood, we used mouse and rat models of Alzheimer's disease with ischemic brain injury, and then delivered Wheat germ agglutinin (WGA)-NPs-miR132 intranasally to treat neurological damage after cerebral ischemia. Synaptic protein expression levels in Alzheimer's mouse models increased significantly after administration. We propose that, nasal delivery of WGA-NPs-miR132 is an interesting novel therapeutic approach for the treatment of neurodegenerative diseases.
27
Reversible middle cerebral artery occlusion without craniectomy in rats.
Enrique Zea Longa, Philip R. Weinstein, Shaun W. Carlson et al. · Stroke · 1989 · 7.5K citations · Full text
Medicine, Neuroscience, Surgery +17
Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy
Sang-Won Min, Seo-Hyun Cho, Yungui Zhou et al. · Neuron · 2010 · 925 citations · Full text
Nasal mucociliary clearance as a factor in nasal drug delivery
E. Marttin, Nicolaas Schipper, J. Coos Verhoef et al. · Advanced Drug Delivery Reviews · 1998 · 461 citations
Lectin-mediated drug delivery:
Claus‐Michael Lehr · Journal of Controlled Release · 2000 · 304 citations